Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.

Pankit Vachhani,Evelyn M Flahavan,Tao Xu,Esprit Ma,Melissa Montez,Anda Gershon,Maika Onishi,Huan Jin,Grace Ku,Brannon Flores,Cat N Bui,Jonathan A Abbas,William Donnellan

The oncologist（2022）

引用 9|浏览8

暂无评分

摘要

This study reflects early real-world experience with venetoclax + HMAs in a predominantly community setting and emphasizes the importance of appropriate venetoclax management in optimizing patient outcomes.

查看译文

关键词

United States,acute,bone marrow,duration of therapy,leukemia,myeloid,retrospective studies,venetoclax

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要